Latest News
Category: News
Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29 – 31, 2020. IPAX-1 is a Phase 1/2 clinical study of TLX101 (also known as 131I-IPA or 4-L-[131I]iodo-phenylalanine) for patients with recurrent glioblastoma multiforme...
Read more
Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings...
Read more
Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for...
Read more
Telix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of...
Read more
ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement...
Read more
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing...
Read more
Telix has submitted a marketing authorisation application (MAA) in Europe for...
Read more
Telix Pharmaceuticals Limited provides a shareholder walkthrough of it’s recently acquired Seneffe manufacturing...
Read more
Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry...
Read more
Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with...
Read more